Teva accuses Corcept, Optime of blocking generic competition for Cushing’s treatment

( June 13, 2024, 19:13 GMT | Official Statement) -- MLex Summary: Teva Pharmaceuticals filed a US antitrust complaint accusing Corcept Therapeutics and Optime Care of illegally blocking generic competition for Corcept’s branded drug Korlym, a treatment for Cushing’s disease. According to the complaint, Corcept manipulated the patent system to delay Food and Drug Administration approval of Teva’s generic competitor by years, and abused the courts through sham litigations that served no purpose but to forestall competition. Teva also claimed Corcept and Optime entered into an unprecedented exclusive-dealing agreement that requires Optime to distribute Corcept’s brand Korlym product but expressly forbids it from distributing any competing products, including Teva’s generic.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.

Know what others in the room don’t, with features including:

Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Teva accuses Corcept, Optime of blocking generic competition for Cushing’s treatment

Prepare for tomorrow’s regulatory change, today

Documents

Related Sections